Find a Clinical Trial

Showing 21 - 30 of 32 Trials

A MULTICENTER, OPEN-LABEL PHASE 1/1B DOSE-FINDING, SAFETY, AND PHARMACOKINETIC STUDY OF MBRC-101, AN ANTI-EPHA5 MONOMETHYL AURISTATIN E(MMAE) ANTIBODY DRUG CONJUGATE, IN ADVANCED REFRACTORY SOLID TUMORS

Principal Investigator:

Linda Y. Wu, MD

Contact Number:

212-342-5162

NCT Number:

NCT06014658

Population:

Adult

Phase:

I

The purpose of this research is to determine the dose and dosing regimens of an investigational drug, MBRC-101, that are well tolerated, as well as to evaluate its safety in patients with advanced or metastatic solid tumors that have already received conventional therapy. MBRC-101 is not an approved treatment anywhere in the world. “Investigational” means that the drug has not been approved by any government authority responsible for the regulation of new medicines, such as the U.S. Food and Drug Administration (FDA). This is the first time MBRC-101 is being tested in humans. Are...
A Multicenter, Open-label, First-in-Human Study of TYRA-430 in Advanced HepatocellularCarcinoma and Other Solid Tumors with Activating FGF/FGFR pathway aberrations (SURF-431)

Principal Investigator:

Ryan H. Moy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT06915753

Population:

Adult

Phase:

I

The purpose of this Study is to find out if an investigational drug, TYRA-430, is safe and effective at treating cancer in participants with locally advanced/metastatic liver cancer and other solid tumors tumors that have a certain mutation or alteration of a type of protein located on the surface of cancer cells. Investigational drug means that it has not been approved by the United States Food and Drug Administration (US FDA) to use or to treat any disease or cancer. This is the first time that the Study Drug has been used in people. Are you Eligible? (Inclusion Criteria) 18 years of age or...
Phase 1 Trial of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Clinical Activity of RP-1664 in Participants with Advanced Solid Tumors

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06232408

Population:

Adult

Phase:

I

The purpose of this study is to learn how well RP-1664 alone works to treat advanced solid tumor. RP-1664 has not been approved by the Food and Drug Administration (FDA). RP- 1664 has not been given to humans prior to this study. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Able to swallow and retail oral medications - Ability to consume a high-fat meal and fast for 12 hours
Safety and Efficacy of Brodalumab in the Treatment of Immune-Related Adverse Events: A PilotStudy

Principal Investigator:

Brian Henick, MD

Contact Number:

212-342-5162

NCT Number:

NCT06673329

Population:

Adult

Phase:

I

The purpose of this study is to test the safety and effectiveness of using brodalumab in patients who develop side effects from cancer immune therapy. Immune-related side effects are due to activation of the immune system in patients who previously received immunotherapy and the goal of this study is to help better control these side effects. Brodalumab is often used to treat patients with autoimmune diseases (diseases where the immune system is activated against normal organs) and safe doses and treatment schedules have been determined in these patients. Immune-related side effects appear to...
First-in-Human, Phase 1/1b, Open-label, Multicenter Study ofBifunctional EGFR/TGFβ Fusion Protein BCA101 Monotherapyand in Combination Therapy in Patients with EGFR-DrivenAdvanced Solid Tumors

Principal Investigator:

Catherine Shu, MD

Contact Number:

212-342-5162

NCT Number:

NCT04429542

Population:

Adult

Phase:

I

This is a first-in-human clinical research study. This study is sponsored by a biopharmaceutical company named Bicara Therapeutics. The main purpose of this study is to investigate the study drug BCA101 alone and BCA101 in combination with pembrolizumab for its safety, the way the body absorbs, distributes, and gets rid of this study drug, how the study drug acts on the body, and whether it works on your cancer in patients with advanced cancer like you. Subjects will receive either BCA101 alone or BCA101 in combination with pembrolizumab until disease worsens, the subject stops benefitting...
Phase 1b, Multicenter, Open-label, Dose Escalation and Dose Expansion Study of RMC-6291 in Combination with RMC-6236 in Participants with Advanced KRASG12C-Mutated Solid Tumors

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06128551

Population:

Adult

Phase:

I

The purpose of this study is to test a combination of 2 new drugs called RMC-6291 and RMC 6236 (the study drugs). RMC-6291 and RMC-6236 are new investigational (ie, experimental) drugs, which means that they are not approved by the United States (US) Food and Drug Administration (FDA) or any other health authorities. This is the first study in which RMC 6291 and RMC-6236 will be tested together in humans. This study will test the safety and anti-tumor effects of RMC-6291 and RMC-6236 when given together at different doses in participants with a change or alteration in the KRASG12C gene within...
Phase 1, open label single-arm two-part study to investigate safety, pharmacokinetics, andpreliminary efficacy of pan-RAF/MEK glue NST-628 oral tablets in subjects with solid tumorsharboring genetic alterations in the MAPK pathway and with other solid

Principal Investigator:

Benjamin Herzberg, MD

Contact Number:

212-342-5162

NCT Number:

NCT06326411

Population:

Adult

Phase:

I

The purpose of this study is to find out if, and at what dose, NST-628 can safely treat solid cancers in patients who have no other treatment options left. NST-628 has been tested in animals and demonstrated some anti-tumor activity. This research study will be the first in which it will be given to humans and is experimental. “Experimental” means that the study drug has not been approved by any government authority responsible for the regulation of new medicines. This trial will explore what doses of NST-628 are safe and tolerable, as well as see whether NST-628 can slow the...
A SINGLE ARM, MULTICENTER, PHASE II, OPEN-LABEL TRIAL TO EVALUATE EFFICACY OF ISATUXIMAB IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE

Principal Investigator:

Divaya Bhutani, MD

Contact Number:

212-342-5162

NCT Number:

NCT04614558

Population:

Adult

Phase:

II

The purpose of this study is to see whether Isatuximab can help improve kidney function of participants with Monoclonal Gammopathy of Renal Significance (MGRS). Isatuximab is approved by the Food and Drug Administration (FDA) for the treatment of adult patients with multiple myeloma, but it is not approved by the FDA to treatMonoclonal Gammopathy of Renal Significance (MGRS). This means that the use of isatuximab in this study is considered ‘investigational’. Are you Eligible? (Inclusion Criteria) • Are you 18 years of age or older? • Do you have persistent renal...
An Open-Label, Multicenter, Phase 1b/2 Study of RP1 in Solid Organ and Hematopoietic Cell Transplant Recipients with Advanced Cutaneous Malignancies

Principal Investigator:

Mariam El-Ashmawy, MD, PhD

Contact Number:

212-342-5162

NCT Number:

NCT04349436

Population:

Adult

Phase:

I/II

This study is being done to find out how effective RP1 is in treating the cancer and how safe it is. These effects could be good (for example, shrinking of tumors) or bad (called side effects). Researchers will study the effects and how long they last. This study is being done to find out how effective RP1 is in treating the cancer and how safe it is. Are you Eligible? (Inclusion Criteria) Are you 18 or older? - Have either kidney, liver, heart, or lung transplant - No history of lung disease
A Phase 1 Basket Study Evaluating the Safety and Feasibility of T-Plex, Autologous Customized T Cell Receptor-Engineered T Cells Targeting Multiple Peptide/HLA Antigens in Participants with Antigen-positive Locally Advanced (Unresectable) or Metastatic

Principal Investigator:

Brian Henick, MD

Contact Number:

212-342-5162

NCT Number:

NCT05973487

Population:

Adult

Phase:

I

The purpose of the study is to learn if the study treatments TSC-204-A0201, TSC 200- A020, and TSC-204-C0702 alone or in combination, referred to as T-Plex, are safe and effective in treating your type of cancer. T-Plex has not yet been approved by the Food and Drug Administration (FDA). This is a first-in-human study, which means that these products have never been administered to humans before. You are unlikely to benefit from taking part in this study. Are you Eligible? (Inclusion Criteria) Must be 18 years or older - Diagnosed with a locally advanced (unresectable) or metastatic solid...

Find a Clinical Trial

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Principal Investigator:

Contact Number:

NCT Number:

Population:

Phase:

Pages